1987 Volume 15 Issue 3 Pages 595-599
Melinamide (N-α-methylbenzyl linoleamide) is known to inhibit hydrolysis of cholesterol ester in intestinal lumen. We studied the effect of melinamide on plasma lipids and lipoproteins of human subjects with dietary cholesterol (chol) loading (6 eggs; 1, 650mg of chol/day). The design was a cross-over trial in which 2 subjects received dietary chol loading for 3 weeks following with ordinary Japanese foods (chol 450mg/day) for 6 weeks. Then same subjects received chol loading with melinamide (2, 250mg/day) for next 3 weeks. Two other subjects received chol loading with melinamide for first 3 weeks, then ordinal Japanese foods for next 6 weeks and chol loading without melinamide for final 3 weeks. Plasma chol and high-density lipoprotein chol (HDL-chol) were determined before and after chol loading with or without melinamide. Mean plasma chol and HDL-chol were increased slightly on chol loading (193±18 to 208±23mg/dl; 58±15 to 64±16mg/dl). But additional melinamide on chol loading did not change plasma chol even though increased HDL-chol significantly (196±4 to 194±7mg/dl; 56±12 to 64±12mg/dl). We also determined plasma chol distribution among lipoproteins separated by agarose column chromatography. Chol loading produced additional lipoprotein chol peak between very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) which appeared to be so-called small VLDL. However additional melinamide could inhibit appearance of small VLDL chol peak. These data suggested that melinamide seemed to be a drug of choice for treatment of hyperlipidemic subjects being affected by dietary cholesterol.
